Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.65 |
| ▸ | CES1 | P23141 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FABP2 | P12104 | 1/20 | 0.41 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2980094 | 1.00 | CES2 (0.65) | CES2CES1LMNAMAPK1TSHR | |
| SCHEMBL7094007 | 1.00 | CES2 (0.65) | CES2CES1LMNAMAPK1TSHR | |
| SCHEMBL10305076 | 0.84 | BLM (0.53) | CES2CES1LMNAMAPK1TSHR | |
| SCHEMBL9987950 | 0.84 | BLM (0.57) | CES2CES1LMNAMAPK1TSHR | |
| SCHEMBL9987952 | 0.84 | BLM (0.57) | CES2CES1LMNAMAPK1TSHR | |
| SCHEMBL23973484 | 0.82 | APP (0.48) | CES2CES1LMNAMAPK1TSHR | |
| SCHEMBL31736719 | 0.82 | AKR1C3 (0.55) | CES2CES1LMNAMAPK1TSHR | |
| SCHEMBL23973474 | 0.82 | MDM2 (0.47) | CES2CES1LMNAMAPK1TSHR | |
| SCHEMBL19716839 | 0.82 | CES2 (0.62) | CES2CES1MMEAKR1C3AKR1C2 | |
| SCHEMBL12658570 | 0.82 | CES2 (0.62) | CES2CES1LMNATSHRMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776920-B2 | Mandelic hydrazides | MERCK PATENT GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20090221712-A1 | MANDELIC HYDRAZIDES | MERCK PATENT GESELLSCHAFT (DE) | 2009-09-03 | — | — | US | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| US-6921758-B2 | Amino acid derivatives | ASTRAZENECA AB (SE) | 2005-07-26 | — | — | US | disclosed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-20040087647-A1 | NEW AMINO ACID DERIVATIVES | ASTRAZENECA AB | 2004-05-06 | — | — | US | disclosed |
| US-6617320-B2 | Protease inhibitor; anticoagulants | ASTRAZENECA AB (SE) | 2003-09-09 | — | — | US | disclosed |
| EP-0836615-B1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | ASTRAZENECA AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| US-6495522-B1 | PREVENTING APOPTOTIC CELL DEATH IN WHICH THE LOSS OF CELLS, TISSUES OR ENTIRE ORGANS OCCURS | CYTOVIA, INC. | 2002-12-17 | — | — | US | disclosed |
| EP-1212295-A1 | SUBSTITUTED $g(a)-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020042396-A1 | Amino acid derivatives | ASTRA AB | 2002-04-11 | — | — | US | disclosed |
| US-6337343-B1 | TREATMENT OF THROMBOSIS WITH ANTICOAGULANTS | ASTRAZENECA AB (SE) | 2002-01-08 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2001016093-A1 | SUBSTITUTED α-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| US-6051568-A | Thrombin inhibitors, their preparation and use | ASTRA AKTIEBOLAG (SE) | 2000-04-18 | — | — | US | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0836615-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | Astra Aktiebolag (SE) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002284-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | ASTRA AKTIEBOLAG (SE) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221712-A1 | MANDELIC HYDRAZIDES | HK1, GLS, AGK | CES2 2492/4885CES1 117/4885LMNA 2306/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | CES2 953/4885CES1 2154/4885LMNA 3391/4885 |
| US-20020042396-A1 | Amino acid derivatives | F2, SERPINC1, ARGLU1 | CES2 4015/4885CES1 625/4885LMNA 3361/4885 |
| US-20040087647-A1 | NEW AMINO ACID DERIVATIVES | F2, ANPEP, PEPD | CES2 3475/4885CES1 351/4885LMNA 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.